<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674852</url>
  </required_header>
  <id_info>
    <org_study_id>20-002505</org_study_id>
    <nct_id>NCT04674852</nct_id>
  </id_info>
  <brief_title>Mayo Designed Soft Tissue Ultrasound-Detectable Marker</brief_title>
  <official_title>A Mayo-Designed Nonmetallic, Ultrasound-Detectable Marker for Metastatic Axillary Lymph Nodes in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine if the Mayo marker is easily seen with ultrasound making&#xD;
      it easier, faster, and more accurate for preoperative localization of the biopsied positive&#xD;
      lymph node.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonrandomized clinical trial to evaluate the Mayo-designed marker for ultrasound conspicuity&#xD;
      at the time of preoperative ultrasound-guided localization.&#xD;
&#xD;
      Study participants are breast cancer patients with pathology-proven metastatic axillary lymph&#xD;
      nodes. Per standard of care, a biopsy marker will have already been associated with the&#xD;
      positive lymph node. 10 such patients scheduled for surgery at Mayo Clinic Rochester, MN with&#xD;
      Dr. James Jakub will be enrolled. Preoperative radioactive seed localization will proceed as&#xD;
      usual, but the marker will be additionally loaded with the seed into the needle using&#xD;
      standard protocol. Before surgery, ultrasound will be performed to evaluate the marker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound detectability</measure>
    <time_frame>Time of placement to surgical resection.</time_frame>
    <description>Evaluation of ultrasound conspicuity of marker placed at time of radioactive seed localization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conspicuity compared to conventional biopsy markers and radioactive seeds</measure>
    <time_frame>Time of placement to surgical resection.</time_frame>
    <description>To compare conspicuity of marker with that of conventional biopsy markers and I-125 localization seeds.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <condition>Ultrasound Therapy; Complications</condition>
  <arm_group>
    <arm_group_label>Marking cN+ nodes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Research Marker</intervention_name>
    <description>The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.</description>
    <arm_group_label>Marking cN+ nodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 18 years or older with breast cancer and biopsy-proven malignant involvement&#xD;
             of an axillary lymph node&#xD;
&#xD;
          -  Surgical management involves preoperative radioactive seed localization of a&#xD;
             previously identified positive axillary lymph node&#xD;
&#xD;
          -  Surgery will be performed by Dr. James Jakub at Mayo Clinic Rochester, MN&#xD;
&#xD;
          -  Radioactive seed localization of an axillary lymph node.&#xD;
&#xD;
          -  No contraception is necessary or required.&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Scheduled for only radioactive seed localizations in the breast (as opposed to axilla)&#xD;
&#xD;
          -  Are pregnant; although the twinkling marker is made of material widely used in&#xD;
             orthopedic procedures, and hence, has an excellent safety profile, the investigators&#xD;
             want to exclude the population of pregnant patients in this phase 0 clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Ramaker, R.N.</last_name>
      <phone>507-538-6984</phone>
      <email>ramaker.sheri@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Christine U. Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>axillary lymph node</keyword>
  <keyword>biopsy clip</keyword>
  <keyword>biopsy marker</keyword>
  <keyword>ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

